Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Farxiga

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

- PMLiVE

AZ loses Crestor patent battle in Australia

Follows challenge from Apotex

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

- PMLiVE

US appeals court upholds AstraZeneca’s Seroquel XR patent

Says patent on unique formulation of antidepressant is valid

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

- PMLiVE

NICE turns down diabetes and ovarian cancer drugs for NHS use

Disappointment for BMS/AZ’s Forxiga and Roche’s Avastin

- PMLiVE

Amgen’s Aranesp disappoints in heart failure

Red blood cell stimulator no better than placebo

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links